{"id":728603,"date":"2023-02-03T08:34:56","date_gmt":"2023-02-03T13:34:56","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/predictive-oncology-appoints-pamela-bush-ph-d-mba-as-chief-business-officer\/"},"modified":"2023-02-03T08:34:56","modified_gmt":"2023-02-03T13:34:56","slug":"predictive-oncology-appoints-pamela-bush-ph-d-mba-as-chief-business-officer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/predictive-oncology-appoints-pamela-bush-ph-d-mba-as-chief-business-officer\/","title":{"rendered":"Predictive Oncology Appoints Pamela Bush, Ph.D., MBA, as Chief Business Officer"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">EAGAN, Minn., Feb.  03, 2023  (GLOBE NEWSWIRE) &#8212; Predictive Oncology Inc.\u00a0(NASDAQ: POAI) is pleased to announce the appointment of Pamela Bush, Ph.D., MBA, as Chief Business Officer. Dr. Bush will lead all business development, partnering and growth strategies for Predictive Oncology.<\/p>\n<p>As a key member of the executive team, Dr. Bush will spearhead the company\u2019s strategic, operational and financial planning initiatives for both existing customers and emerging new markets. She will work closely with the company\u2019s senior management in leveraging and expanding its portfolio of proprietary solutions to advance drug discovery and enable oncology drug development for the company\u2019s biopharma partners.<\/p>\n<p>\u201cIn terms of scientific intelligence, industry insight and understanding the business of biopharma, Pamela is at the top of her game,\u201d said Raymond F. Vennare, Chief Executive Officer and Chairman of the Board for Predictive Oncology. \u201cShe honed these skills over twenty years of experience analyzing emerging markets in life sciences, capital formation for early-stage companies and, most recently, leading business development efforts for Eli Lilly &amp; Company.\u201d<\/p>\n<p>Dr. Bush previously served as Senior Vice President of Strategic Sales and Business Development at Predictive Oncology. In that role, she was instrumental in guiding the company\u2019s strategic direction, expanding its product offerings and launching commercialization efforts for the company\u2019s flagship technology platform.<\/p>\n<p>\u201cWe have the power to change the way drugs are discovered and developed. I\u2019m looking forward to further impacting the future of oncology drug discovery and driving adoption of solutions that can move compounds into clinical trials faster and with higher confidence,\u201d noted Dr. Bush. \u201cThese efforts collectively benefit our partners, investors and other stakeholders, but most importantly, cancer patients waiting for therapies to be developed.\u201d<\/p>\n<p>Dr. Bush brings more than twenty years of experience in venture creation, finance and business development in the life sciences industry. Before joining\u00a0Predictive Oncology in December of 2021, Dr. Bush worked at Eli Lilly &amp; Company in various roles including Corporate Business Development, Finance and Patient Services. She served as the Director of Immunology at Lilly Patient Services, Eli Lilly &amp; Company, primarily focusing on managing vendor performance and relationships, as well as negotiating contracts and finding workflow efficiencies. Before that, Dr. Bush served as Director of Corporate Business Development at Eli Lilly &amp; Company. She was also the founder and managing partner of\u00a0BluGene Consulting, a consultancy supporting emerging life science companies that focused on new client acquisition and private investor fundraising. Throughout her career, Dr. Bush has supported the creation and growth of more than\u00a0100 life sciences start-ups.<\/p>\n<p>Dr. Bush currently serves on the Board of Directors for Cvergenx, is a frequent presenter on oncology drug discovery and serves in various volunteering and mentorship roles. She earned her Ph.D. in Biology from Carnegie Mellon University (CMU) and MBA from CMU\u2019s Tepper School of Business.<\/p>\n<p>\n        <strong>About Predictive Oncology<\/strong><br \/>\n        <br \/>As a science-driven company on the leading edge of oncology drug discovery, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-esZ2yW8xK9Di7ftxJ4t1KTl75FxXbgyy8DHr-5sq4Yg9qrAezsnx0nVzsZS2ElSnydru35dtrT1RiLWxQtaBUBVzl9omvtUhuXt29PKmQs=\" rel=\"nofollow noopener\" target=\"_blank\">Predictive Oncology<\/a> (NASDAQ: POAI) offers an unrivaled suite of solutions for the biopharma industry. Through the integration of scientific rigor and machine learning, the company has developed the ability to advance molecules into medicine more confidently by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the world\u2019s largest privately held biobank of over 150K tumor samples. Predictive Oncology\u2019s solutions additionally include tumor models, biologics development, formulation design, a GMP facility, a CLIA laboratory and substantial scientific domain expertise.<\/p>\n<p>\n        <strong>Public Relations Contact:<\/strong><br \/>\n        <br \/>Predictive Oncology<br \/>Theresa Ferguson<br \/>(630) 566-2003<br \/>tferguson@predictive-oncology.com<\/p>\n<p>\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>Landon Capital <br \/>Keith Pinder<br \/>(404) 995-6671<br \/>kpinder@landoncapital.net<\/p>\n<p>\n        <strong>Forward-Looking Statements:<\/strong><br \/>\n        <br \/>Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, changes in management, plans and objectives of management are forward-looking statements. The words \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cwould,\u201d \u201ctarget\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading \u201cRisk Factors\u201d in our filings with the\u00a0SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.<\/p>\n<p>A photo accompanying this announcement is available at:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=34qqXfuS0xJm0Sc8apzla1xmdLVwPzS_QU9U-mIderdvcuw4YwZmys6EtDxLOI2tK7h-Sd4m2JP5hQPGiZHTe6mx6YINUDq1EPOSNWgPkew2gIdEza6vhfI2cEm3MHcC89MjcXurE67Vqc2ro52BxXJMyEVvJ66cdPnZVEcCpE8xC2K-9PY7arXWmJoAj1X5Cw53_F_EsLRZdryltpkRiLvVeuZ5-hbzj54wkEJZyvyk3wrq54fJ503bob_dSdzZAlxAiUJIxY7vZQ8ZMbzfkw==\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/cada4887-bc29-4bb7-92cd-e33ad206ad4b<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MjE5NyM1MzkwMDIwIzIwMTkyMjY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/Y2E1NmQxMjYtZjJkOC00Y2Y3LThmZWYtMGE2OWYyMDk4NjU5LTEwMzA3OTk=\/tiny\/Predictive-Oncology-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>EAGAN, Minn., Feb. 03, 2023 (GLOBE NEWSWIRE) &#8212; Predictive Oncology Inc.\u00a0(NASDAQ: POAI) is pleased to announce the appointment of Pamela Bush, Ph.D., MBA, as Chief Business Officer. Dr. Bush will lead all business development, partnering and growth strategies for Predictive Oncology. As a key member of the executive team, Dr. Bush will spearhead the company\u2019s strategic, operational and financial planning initiatives for both existing customers and emerging new markets. She will work closely with the company\u2019s senior management in leveraging and expanding its portfolio of proprietary solutions to advance drug discovery and enable oncology drug development for the company\u2019s biopharma partners. \u201cIn terms of scientific intelligence, industry insight and understanding the business of biopharma, Pamela is at the top of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/predictive-oncology-appoints-pamela-bush-ph-d-mba-as-chief-business-officer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Predictive Oncology Appoints Pamela Bush, Ph.D., MBA, as Chief Business Officer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-728603","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Predictive Oncology Appoints Pamela Bush, Ph.D., MBA, as Chief Business Officer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/predictive-oncology-appoints-pamela-bush-ph-d-mba-as-chief-business-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Predictive Oncology Appoints Pamela Bush, Ph.D., MBA, as Chief Business Officer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"EAGAN, Minn., Feb. 03, 2023 (GLOBE NEWSWIRE) &#8212; Predictive Oncology Inc.\u00a0(NASDAQ: POAI) is pleased to announce the appointment of Pamela Bush, Ph.D., MBA, as Chief Business Officer. Dr. Bush will lead all business development, partnering and growth strategies for Predictive Oncology. As a key member of the executive team, Dr. Bush will spearhead the company\u2019s strategic, operational and financial planning initiatives for both existing customers and emerging new markets. She will work closely with the company\u2019s senior management in leveraging and expanding its portfolio of proprietary solutions to advance drug discovery and enable oncology drug development for the company\u2019s biopharma partners. \u201cIn terms of scientific intelligence, industry insight and understanding the business of biopharma, Pamela is at the top of &hellip; Continue reading &quot;Predictive Oncology Appoints Pamela Bush, Ph.D., MBA, as Chief Business Officer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/predictive-oncology-appoints-pamela-bush-ph-d-mba-as-chief-business-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-03T13:34:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MjE5NyM1MzkwMDIwIzIwMTkyMjY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/predictive-oncology-appoints-pamela-bush-ph-d-mba-as-chief-business-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/predictive-oncology-appoints-pamela-bush-ph-d-mba-as-chief-business-officer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Predictive Oncology Appoints Pamela Bush, Ph.D., MBA, as Chief Business Officer\",\"datePublished\":\"2023-02-03T13:34:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/predictive-oncology-appoints-pamela-bush-ph-d-mba-as-chief-business-officer\\\/\"},\"wordCount\":796,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/predictive-oncology-appoints-pamela-bush-ph-d-mba-as-chief-business-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MjE5NyM1MzkwMDIwIzIwMTkyMjY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/predictive-oncology-appoints-pamela-bush-ph-d-mba-as-chief-business-officer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/predictive-oncology-appoints-pamela-bush-ph-d-mba-as-chief-business-officer\\\/\",\"name\":\"Predictive Oncology Appoints Pamela Bush, Ph.D., MBA, as Chief Business Officer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/predictive-oncology-appoints-pamela-bush-ph-d-mba-as-chief-business-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/predictive-oncology-appoints-pamela-bush-ph-d-mba-as-chief-business-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MjE5NyM1MzkwMDIwIzIwMTkyMjY=\",\"datePublished\":\"2023-02-03T13:34:56+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/predictive-oncology-appoints-pamela-bush-ph-d-mba-as-chief-business-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/predictive-oncology-appoints-pamela-bush-ph-d-mba-as-chief-business-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/predictive-oncology-appoints-pamela-bush-ph-d-mba-as-chief-business-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MjE5NyM1MzkwMDIwIzIwMTkyMjY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MjE5NyM1MzkwMDIwIzIwMTkyMjY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/predictive-oncology-appoints-pamela-bush-ph-d-mba-as-chief-business-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Predictive Oncology Appoints Pamela Bush, Ph.D., MBA, as Chief Business Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Predictive Oncology Appoints Pamela Bush, Ph.D., MBA, as Chief Business Officer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/predictive-oncology-appoints-pamela-bush-ph-d-mba-as-chief-business-officer\/","og_locale":"en_US","og_type":"article","og_title":"Predictive Oncology Appoints Pamela Bush, Ph.D., MBA, as Chief Business Officer - Market Newsdesk","og_description":"EAGAN, Minn., Feb. 03, 2023 (GLOBE NEWSWIRE) &#8212; Predictive Oncology Inc.\u00a0(NASDAQ: POAI) is pleased to announce the appointment of Pamela Bush, Ph.D., MBA, as Chief Business Officer. Dr. Bush will lead all business development, partnering and growth strategies for Predictive Oncology. As a key member of the executive team, Dr. Bush will spearhead the company\u2019s strategic, operational and financial planning initiatives for both existing customers and emerging new markets. She will work closely with the company\u2019s senior management in leveraging and expanding its portfolio of proprietary solutions to advance drug discovery and enable oncology drug development for the company\u2019s biopharma partners. \u201cIn terms of scientific intelligence, industry insight and understanding the business of biopharma, Pamela is at the top of &hellip; Continue reading \"Predictive Oncology Appoints Pamela Bush, Ph.D., MBA, as Chief Business Officer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/predictive-oncology-appoints-pamela-bush-ph-d-mba-as-chief-business-officer\/","og_site_name":"Market Newsdesk","article_published_time":"2023-02-03T13:34:56+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MjE5NyM1MzkwMDIwIzIwMTkyMjY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/predictive-oncology-appoints-pamela-bush-ph-d-mba-as-chief-business-officer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/predictive-oncology-appoints-pamela-bush-ph-d-mba-as-chief-business-officer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Predictive Oncology Appoints Pamela Bush, Ph.D., MBA, as Chief Business Officer","datePublished":"2023-02-03T13:34:56+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/predictive-oncology-appoints-pamela-bush-ph-d-mba-as-chief-business-officer\/"},"wordCount":796,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/predictive-oncology-appoints-pamela-bush-ph-d-mba-as-chief-business-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MjE5NyM1MzkwMDIwIzIwMTkyMjY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/predictive-oncology-appoints-pamela-bush-ph-d-mba-as-chief-business-officer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/predictive-oncology-appoints-pamela-bush-ph-d-mba-as-chief-business-officer\/","name":"Predictive Oncology Appoints Pamela Bush, Ph.D., MBA, as Chief Business Officer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/predictive-oncology-appoints-pamela-bush-ph-d-mba-as-chief-business-officer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/predictive-oncology-appoints-pamela-bush-ph-d-mba-as-chief-business-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MjE5NyM1MzkwMDIwIzIwMTkyMjY=","datePublished":"2023-02-03T13:34:56+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/predictive-oncology-appoints-pamela-bush-ph-d-mba-as-chief-business-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/predictive-oncology-appoints-pamela-bush-ph-d-mba-as-chief-business-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/predictive-oncology-appoints-pamela-bush-ph-d-mba-as-chief-business-officer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MjE5NyM1MzkwMDIwIzIwMTkyMjY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MjE5NyM1MzkwMDIwIzIwMTkyMjY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/predictive-oncology-appoints-pamela-bush-ph-d-mba-as-chief-business-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Predictive Oncology Appoints Pamela Bush, Ph.D., MBA, as Chief Business Officer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/728603","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=728603"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/728603\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=728603"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=728603"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=728603"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}